Farmas USA

Amarin highlights clinical benefits of Vascepa with presentation of new study

• A new analysis supported by Amarin Corporation (AMRN +1.1%) and presented at the ongoing International Stroke Conference 2021 highlights the clinical impact of VASCEPA® (icosapent ethyl), the company said.
• The presentation of REDUCE-IT® STROKE as announced by HLS Therapeutics (OTCPK:HLTRF) includes an analysis of the stroke rates across the enrolled patient population (n=8179).
• Event rates for time to first fatal or nonfatal stroke: 2.4% for VASCEPA vs. 3.3% for placebo with a relative risk reduction (“RRR”) of 28% (p=0.01).
• Ischemic stroke time to first event rates: 2.0% for VASCEPA vs. 3.0% for placebo at a RRR of 36% (p=0.002).
• However, there was no significant difference between VASCEPA vs. placebo (0.3% vs 0.2%; p=0.55) for hemorrhagic stroke which occurred at low rates.
• VASCEPA, sales of which rose at a record ~17% YoY in Q4 2020 is approved in the U.S., Canada, Lebanon, and the UAE.